Plain-English translation of NCT07671378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether zanubrutinib combined with sonrotoclax can help people with newly diagnosed, high-risk chronic lymphocytic leukemia (a blood cancer). The study will measure how well this medication combination works and how safe it is. Researchers will use blood tests to monitor how well the cancer responds, and may adjust how long you take the treatment based on those results.
High-risk forms of this blood cancer can be harder to treat and may not respond as well to standard approaches. This trial is testing whether this new medication combination might be more effective for patients with these harder-to-treat forms of the disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication combination by mouth on a set schedule. You would visit the research center regularly for blood tests and scans to monitor how your cancer responds. The length of treatment is guided by MRD (minimal residual disease) testing — a sensitive blood test that looks for remaining cancer cells — so your treatment schedule may be adjusted based on how well you respond.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~24 participants
Started
June 2026
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huayuan ZHU, MD, phD
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.